You searched for cnsp - Page 4 of 22

Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study

Cancer drug developer CNS Pharmaceuticals (NASDAQ: CNSP) is closer to reporting the results of its drive toward a new treatment for the effectively incurable brain cancer glioblastoma (“GBM”), with 200 of the expected 243 patients now enrolled in the company’s potentially pivotal study involving its flagship drug candidate Berubicin, according to a company news release … Continue reading “Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”) and neuro-oncology, recently presented updated safety results from its potentially pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin. “Most notably, this novel anthracycline demonstrated its capability to be … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients”

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”), and neuro-oncology, recently announced the presentation of updated safety results from its potentially pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin. Most notably, this novel anthracycline demonstrated its … Continue reading “CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced enrollment of 200 of the expected 243 patients in the company’s ongoing potentially pivotal study evaluating Berubicin for the treatment of recurrent Glioblastoma Multiforme (“GBM”), an aggressive … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, in New York City. According to the announcement, CNS … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its financial results for the quarter ended June 30, 2023, provided a corporate update and reiterated upcoming milestones. “We are approaching the most important milestone to date … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q2 2023 Results, Presents Updated Findings from Potentially Pivotal Study of Berubicin”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities

CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already produced one patient with over 15 years of GBM survival. “Berubicin distinguishes itself by being virtually unique in its status … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, released an update on its ongoing clinical study evaluating Berubicin for the treatment of recurrent GBM, an aggressive and incurable form of brain cancer. According to the report, the company continues … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference”

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract Selected for Poster Presentation at 2023 SNO/ASCO CNS Cancer Conference

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its abstract was selected for in-person poster presentation at the 2023 SNO/ASCO CNS Cancer Conference taking place in San Francisco from Aug. 10-12, … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract Selected for Poster Presentation at 2023 SNO/ASCO CNS Cancer Conference”

National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)

National awareness of glioblastoma tumors (“GBM”) sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond three years U.S.-based drug developer CNS Pharmaceuticals is in the midst of a global potentially pivotal … Continue reading “National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)”

Site Search

Company Search

Search Results for: cnsp